Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression

TP53 gene mutations occur in 70% of oesophageal adenocarcinomas (OACs). Given the central role of p53 in controlling cellular response to therapy we investigated the role of mutant (mut-) p53 and SLC7A11 in a CRISPR-mediated JH-EsoAd1 TP53 knockout model. Response to 2 Gy irradiation, cisplatin, 5-F...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichelmann, Ann-Kathrin, Mayne, George C., Chiam, Karen, Due, Steven L., Bastian, Isabell, Butz, Frederike, Wang, Tingting, Sykes, Pamela J., Clemons, Nicholas J., Liu, David S., Michael, Michael Z., Karapetis, Christos S., Hummel, Richard, Watson, David I., Hussey, Damian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197322/
https://www.ncbi.nlm.nih.gov/pubmed/34074015
http://dx.doi.org/10.3390/ijms22115547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197322/
https://www.ncbi.nlm.nih.gov/pubmed/34074015
http://dx.doi.org/10.3390/ijms22115547

Ejemplares similares